Verekitug

DB19096InvestigationalProtein Based Therapies

Verekitug is under investigation in clinical trial NCT06164704 (A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps).

Mechanism: Pharmacologically active on Cytokine receptor-like factor 2
Curator reviewed
Code names: ASP-7266 · UPB-101

Resolves to

Compound

UNIIT1NAO7YDA7CAS2768386-15-6

Targets

Q9HC73CRLF2

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Verekitug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account